Cargando…
Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
PURPOSE: To assess outcomes and recovery strategy of patients undergoing intravitreal injections for exudative age-related macular degeneration who experienced COVID-19 related interruption in treatment during complete lockdown. METHODS: This was a retrospective, observational case study. We used a...
Autores principales: | Allegrini, Davide, Raimondi, Raffaele, Montesano, Giovanni, Borgia, Alfredo, Sorrentino, Tania, Tsoutsanis, Panagiotis, Romano, Mario R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517983/ https://www.ncbi.nlm.nih.gov/pubmed/34675475 http://dx.doi.org/10.2147/OPTH.S323058 |
Ejemplares similares
-
Outcomes of Abrupt Switch to Bevacizumab of Patients Undergoing Aflibercept Intravitreal Injections for Neovascular Age-Related Macular Degeneration in a Tertiary Center in Lombardy, Italy: A Real-Life Retrospective Analysis
por: Randazzo, Alessandro, et al.
Publicado: (2021) -
Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Non-Age-Related Macular Degeneration
por: Salehipour, Masoud, et al.
Publicado: (2010) -
Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration
por: Riazi-Esfahani, Mohammad, et al.
Publicado: (2008) -
Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
por: Ghazi, Nicola G, et al.
Publicado: (2010) -
Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
por: Fang, Kai, et al.
Publicado: (2013)